Cranberry Proanthocyanidins Mitigate Reflux-Induced Transporter Dysregulation in an Esophageal Adenocarcinoma Model
We recently reported that cranberry proanthocyanidins (C-PACs) inhibit esophageal adenocarcinoma (EAC) by 83% through reversing reflux-induced bacterial, inflammatory and immune-implicated proteins and genes as well as reducing esophageal bile acids, which drive EAC progression. This study investiga...
Saved in:
Main Authors: | Yun Zhang (Author), Katherine M. Weh (Author), Bridget A. Tripp (Author), Jennifer L. Clarke (Author), Connor L. Howard (Author), Shruthi Sunilkumar (Author), Amy B. Howell (Author), Laura A. Kresty (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cranberries and Cancer: An Update of Preclinical Studies Evaluating the Cancer Inhibitory Potential of Cranberry and Cranberry Derived Constituents
by: Katherine M. Weh, et al.
Published: (2016) -
Characterizing isoform switching events in esophageal adenocarcinoma
by: Yun Zhang, et al.
Published: (2022) -
Cranberry proanthocyanidins inhibit the adherence properties of <it>Candida albicans </it>and cytokine secretion by oral epithelial cells
by: Feldman Mark, et al.
Published: (2012) -
Cranberry Proanthocyanidins as a Therapeutic Strategy to Curb Metabolic Syndrome and Fatty Liver-Associated Disorders
by: Francis Feldman, et al.
Published: (2022) -
Assessing the treatment effect of cranberry type A proanthocyanidins on vulvovaginal candidiasis: a randomised controlled clinical interventional study
by: Yueyue Chen, et al.
Published: (2024)